Abstract:Changying Niu, 1 Shenxing Tan 2 1 Dermatological Department, Affiliated Hospital of Weifang Medical University, Weifang, People's Republic of China; 2 Plastic Surgery, Affiliated Hospital of Weifang Medical University, Weifang, People's Republic of China Correspondence: Shenxing Tan, Tel +86 18754411279, Email Background: Long non-coding RNAs (lncRNAs) play an important role in the occurrence of melanoma. However, the specific molecular mechanisms that regulate its biological function are still poorly understood. Therefore, the main purpose of this study is to elucidate the internal mechanism of lncRNA-FENDRR as a biological marker for the occurrence of SKCM and its influence on its proliferation. Results: FENDRR is low expressed in skin cutaneous melanoma (SKCM) tissues and appears to be at an even lower level as the tumor progresses. However, the high expression of FENDRR can affect the proliferation of SKCM cell line A375. The results of flow cytometry showed that after overexpression of FENDRR, the cell cycle was arrested in the G1/G0 phase. Bioinformatics analysis and RIP results showed that FENDRR could be combined with YTHDF1. Together, these complexes regulate c-Myc mRNA level and determine cell proliferation. Conclusion: We found that overexpression of FENDRR can effectively inhibit SKCM, which provides a new theoretical basis for new therapeutic approaches and targeted RNA drugs. Keywords: long non-coding RNAs, FENDRR, melanoma, cell proliferation Cutaneous melanoma is a kind of highly aggressive and metastatic cancer. 1 It only occurs in 5% of all skin cancers but causes more than 75% of deaths. 2,3 Melanoma can be cured by surgical removal at an early stage. 4 However, when the disease progresses to an advanced stage (stage IV), the 5-year survival rate of patients decreases significantly, even to less than 20%. 2 There have been a variety of methods in clinical treatment for advanced melanoma, such as radiotherapy, chemotherapy, immunotherapy or targeted therapy. 5 Recent studies on the combination of immunotherapy and radiotherapy on melanoma found that this is a safe and promising way on melanoma treatment. 6 However, the survival rate of patients has not been effectively improved. Therefore, more efforts are still needed on the exploration of the pathogenesis of melanoma. Long non-coding RNAs (lncRNAs) were regarded as transcriptional noise at the initial stage of discovery. With in-depth studies, more and more lncRNAs have been proven to have specific functions. 7,8 Especially, it is closely related to the occurrence of many cancers. 9–13 For example, it has been found that lncRNA can affect histone H3 methylation by binding with EZH2, thus affecting p21 expression to regulate the proliferation of fine lung cancer. 14 In addition, recent studies have found that lncRNA can also regulate gene expression by affecting mRNA stability, thus affecting the occurrence of diseases. LncRNA-MEG3 can bind to PTBP1 and thus affect the degradation of SHP mRNA, leading to liver injury. 15 In general, lncRNAs are involved in the pathogenesis of a variety of diseases, especially cancer. In this study, we found that lncRNA-FENDRR had a low expression level in SKCM tissues. However, low expression of FENDRR can lead to tumor deterioration and promote tumor cell proliferation. The internal mechanism of this phenomenon is discussed and deeply studied. This paper provides a potential diagnostic target for the diagnosis of SKCM. Melanoma tissue and para-cancer tissue were collected from the Affiliated Hospital of Weifang Medical University between 2016 and 2022. Melanoma patients were recruited from the Affiliated Hospital of Weifang medical university between 2016 and 2022. This study was approved by the Affiliated Hospital of Weifang Medical University Ethics Committee, and the written informed consent of all participants was obtained before recruitment. Melanoma is confirmed by pathological examination. Clinical data have been collected and collated for clinicopathological analysis. All the procedures conform with the Declaration of Helsinki. 16 A375 cells were purchased from Procell Life Science & Technology (Wuhan, China) and were cultured in basic medium with 100mL MEM (Gibco, 12492013, USA), 10mL Fetal Bovine Serum, FBS (Gibco, 10270-106, USA), 0.3mL gentamicin solution and 3mL 7.5% sodium carbonate solution. During cell passage, the cells were digested with 0.25% trypsin solution, until the cells were completely shed. Add cell culture medium to terminate digestion and pack according to the required proportion of passage. During transfection, 5μg plasmid was premixed with 20μL LIPO2000 (Inv -Abstract Truncated-

CX-F9, a Novel RSK2 Inhibitor, Suppresses Cutaneous Melanoma Cells Proliferation and Metastasis Through Regulating Autophagy.

A novel ribosomal protein S6 kinase 2 inhibitor attenuates the malignant phenotype of cutaneous malignant melanoma cells by inducing cell cycle arrest and apoptosis

RSK2 promotes melanoma cell proliferation and vemurafenib resistance via upregulating cyclin D1

A Novel Multikinase Inhibitor R8 Exhibits Potent Inhibition on Cancer Cells Through Both Apoptosis and Autophagic Cell Death

Discovery of novel p90 ribosomal S6 kinase 2 inhibitors for potential cancer treatment through ligand-based and structure-based virtual screening methods

CXCR7 Promotes Melanoma Tumorigenesis Via Src Kinase Signaling

LncRNA FENDRR Suppresses Melanoma Growth via Influencing c-Myc mRNA Level

Preclinical Evaluation of a Novel Orally Available SRC/Raf/VEGFR2 Inhibitor, SKLB646, in the Treatment of Triple-Negative Breast Cancer

Targeting RSK2 in Cancer Therapy: A Review of Natural Products

Discovery of a novel dual-target inhibitor against RSK1 and MSK2 to suppress growth of human colon cancer

Abstract 602: Targeting CDK9 with a novel potent and selective inhibitor, YX0798, in CAR-T-relapsed mantle cell lymphoma models

AMPK Activation by GSK621 Inhibits Human Melanoma Cells in Vitro and in Vivo.

Deciphering the tumor-suppressive role of PSMB9 in melanoma through multi-omics and single-cell transcriptome analyses

Pharmacological Targeting of STK19 Inhibits Oncogenic NRAS-Driven Melanomagenesis.

The novel CDK9 inhibitor, XPW1, alone and in combination with BRD4 inhibitor JQ1, for the treatment of clear cell renal cell carcinoma

Knockdown of FBXO22 inhibits melanoma cell migration, invasion and angiogenesis via the HIF-1α/VEGF pathway

Potential use of kiwifruit extract for treatment of melanoma

The FGF2-binding Peptide P7 Inhibits Melanoma Growth in Vitro and in Vivo

System analysis based on the pyroptosis-related genes identifes GSDMD as a novel therapy target for skin cutaneous melanoma

The ERK inhibitor GDC-0994 selectively inhibits growth of BRAF mutant cancer cells

Microparticle-Delivered Cxcl9 Prolongs Braf Inhibitor Efficacy in Melanoma